The Value of Total antioxidant Status and Serum Tumor Necrosis Factor-α Levels at 24–28 Weeks of Gestation in the Prediction of Optimal Treatment Protocol in Gestational Diabetes Mellitus

Abstract

Aim: The aim of this study was to investigate the serum oxidative stress markers, antioxidant enzyme and tumor necrosis factor-α (TNF-α) levels at 24–28 weeks of gestation and to evaluate the predictive value of them on the subsequent treatment protocol in gestational diabetes mellitus (GDM).

Methods: A total of 58 GDM patients (30 treated with only conventional healthy dietary recommendation (CHDR), 28 treated with insulin) and 30 healthy pregnant women at 24–28 weeks of gestation, were enrolled in this prospective case-control study. The oxidative status, antioxidant enzyme and TNF-α levels were evaluated to determine if there is an association with the need of insulin therapy for glycemic control by using multivariable logistic regression analysis.

Results: TNF-α (OR=11.976, 95%CI: 2.441–58.754, P=0.002) and total antioxidant status (TAS) (OR=12.769, 95%CI: 2.464–66.182, P=0.002) were found to be predictive for GDM at 24–28 weeks of gestation. Besides, further evaluation considering the treatment modality showed that increased TNF-α (OR=18.615, 95%CI: 2.338–148.240, P=0.006) and lower TAS levels (OR=99.471, 95%CI: 2.865–3 453.061, P=0.011) were independent predictors of the need for insulin treatment in GDM patients.

Conclusions: Increased TNF-α levels and low TAS are significantly associated with the increased risk of insulin requirement for achieving good glycemic control in GDM.

Key words

gestational diabetes mellitus - insulin requirement - oxidative stress - tumor necrosis factor-α

• References

• 1 Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. Diabetes Res Clin Pract 1999; 44: 21-26
• 2 Ricart W, Lopez J, Mozas J. et al. Potential impact of American Diabetes Association (2000) criteria for diagnosis of gestational diabetes mellitus in Spain. Diabetologia 2005; 48: 1135-1141
• 3 Eriksson UJ, Cederberg J, Wentzel P. Congenital malformations in offspring of diabetic mothers–animal and human studies. Rev Endocr Metab Disord 2003; 4: 79-93
• 4 Seghieri G, Tesi F, De Bellis A. et al. Long term predictors of post-partum glucose metabolism in women with gestational diabetes mellitus. Exp Clin Endocrinol Diabetes 2010; 118: 485-489
• 5 Greene MF, Solomon CG. Gestational diabetes mellitus – time to treat. N Engl J Med 2005; 352: 2544-2546
• 6 Langer O, Yogev Y, Most O. et al. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 2005; 192: 989-997
• 7 Coustan DR, Lowe LP, Metzger BE. et al. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 2010; 202: 654e1-654e6
• 8 West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000; 17: 171-180
• 9 Biri A, Onan A, Devrim E. et al. Oxidant status in maternal and cord plasma and placental tissue in gestational diabetes. Placenta 2006; 27: 327-332
• 10 Karacay O, Sepici-Dincel A, Karcaaltincaba D. et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in preeclampsia and gestational diabetic patients in 24–36 weeks of gestation. Diabetes Res Clin Pract 2010; 89: 231-238
• 11 Coughlan MT, Permezel M, Georgiou HM. et al. Repression of oxidant-induced nuclear factor-κB activity mediates placental cytokine responses in gestational diabetes. J Clin Endocrinol Metab 2004; 89: 3585-3594
• 12 Qiu C, Hevner K, Abetew D. et al. Oxidative DNA damage in early pregnancy and risk of gestational diabetes mellitus: A pilot study. Clin Biochem 2011; 44: 804-808
• 13 Nair SP, Shah NC, Taggarsi A. et al. PON1 and its association with oxidative stress in type I and type II diabetes mellitus. Diabetes Metab Syndr 2011; 5: 126-129
• 14 Nowak M, Wielkoszynski T, Marek B. et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med 2010; 10: 185-192
• 15 Camuzcuoglu H, Toy H, Cakir H. et al. Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus. J Womens Health (Larchmt) 2009; 18: 1435-1439
• 16 Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity, and diabetes. Trends Immunol 2004; 25: 4-7
• 17 Richardson AC, Carpenter MW. Inflammatory mediators in gestational diabetes. Obstet Gynecol Clin North Am 2007; 34: 213-224
• 18 Kim C, Cheng YJ, Beckles GL. Inflammation among women with a history of gestational diabetes mellitus and diagnosed diabetes in the Third National Health and Nutrition Examination Survey. Diabetes Care 2008; 31: 1386-1388
• 19 Kirwan JP, Hauguel-De Mouzon S, Lepercq J. et al. TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 2002; 51: 2207-2213
• 20 Kleinwechter H, Schafer-Graf U, Buhrer C. et al. Gestational diabetes mellitus (GDM) diagnosis, therapy and follow-up care: Practice Guideline of the German Diabetes Association(DDG) and the German Association for Gynaecologyand Obstetrics (DGGG). Exp Clin Endocrinol Diabetes 2014; 122: 395-405
• 21 Armstrong CL, Brown LP, York R. et al. From diagnosis to home management: nutritional considerations for women with gestational diabetes. Diabetes Educ 1991; 17: 455-459
• 22 Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111
• 23 Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation more stable ABTS radical cation. Clin Biochem 2004; 37: 277-285
• 24 Wendland EM, Duncan BB, Mengue SS. et al. Lesser than diabetes hyperglycemia in pregnancy is related to perinatal mortality: a cohort study in Brazil. BMC Pregnancy Childbirth 2011; 11: 92
• 25 Kintiraki E, Goulis DG, Mameletzi S. et al. Large- and small-for-gestational-age neonates born by women with gestational diabetes mellitus diagnosed by the new IADPSG criteria: a case-control study of 289 patients and 1 108 controls. Exp Clin Endocrinol Diabetes 2013; 121: 262-265
• 26 Rudge MV, Calderon IM, Ramos MD. et al. Perinatal outcome of pregnancies complicated by diabetes and by maternal daily hyperglycemia not related to diabetes. A retrospective 10-year analysis. Gynecol Obstet Invest 2000; 50: 108-112
• 27 McElvy SS, Miodovnik M, Rosenn B. et al. A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med 2000; 9: 14-20
• 28 Crowther CA, Hiller JE, Moss JR. et al. Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group . Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 2477-2486
• 29 Clayton Jr W, Agarwal N, Wang L. et al. Clinical markers implying the need for treatment in women with gestational diabetes mellitus. Endocr Pract 2012; 18: 62-65
• 30 Bakiner O, Bozkirli E, Ozsahin K. et al. Risk factors that can predict antenatal insulin need in gestational diabetes. J Clin Med Res 2013; 5: 381-388
• 31 Ouzounian JG, Rosenheck R, Lee RH. et al. One-hour post-glucola results and pre-pregnancy body mass index are associated with the need for insulin therapy in women with gestational diabetes. J Matern Fetal Neonatal Med 2011; 24: 718-722
• 32 Chen H, Yang Y, Hu X. et al. Tumor necrosis factor alpha mRNA and protein are present in human placental and uterine cells in early and late stages of gestation. Am J Pathol 1991; 139: 327-335
• 33 Moreli JB, Morceli G, De Luca AK. et al. Influence of maternal hyperglycemia on IL-10 and TNF-α production: the relationship with perinatal outcomes. J Clin Immunol 2012; 32: 604-610
• 34 Melczer Z, Banhidy F, Csomor S. et al. Role of tumour necrosis factor-alpha in insulin resistance during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 105: 7-10
• 35 Walsh JM, McGowan CA, Byrne JA. et al. The association between TNF-α and insulin resistance in euglycemic women. Cytokine 2013; 64: 208-212
• 36 Winkler G, Cseh K, Baranyi E. et al. Tumor necrosis factor system in insulin resistance in gestational diabetes. Diabetes Res Clin Pract 2002; 56: 93-99
• 37 Peuchant E, Brun JL, Rigalleau V. et al. Oxidative and antioxidative status in pregnant women with either gestational or type 1 diabetes. Clin Biochem 2004; 37: 293-298
• 38 Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412
• 39 Coughlan MT, Vervaart PP, Permezel M. et al. Altered placental oxidative stress status in gestational diabetes mellitus. Placenta 2004; 25: 78-84